The math reveals an uncomfortable truth: GLP-1 utilization tells only part of the metabolic health story. New analysis from the Peterson-KFF Health System Tracker examined GLP-1 utilization patterns across employer-sponsored insurance plans. The headline finding: 15% of covered adults used a GLP-1 in 2023. But with 42% of U.S. adults meeting obesity criteria, a significant…
Tag: Thought Leadership
What the Evidence Says About Weight Management Programs That Actually Last
The GLP-1 durability conversation has established something important: medication alone doesn't produce lasting weight management outcomes for most patients. The Oxford BMJ meta-analysis (West et al., 2026) documented regain roughly 4x faster after stopping GLP-1s than after behavioral interventions. CMS is designing its BALANCE Model around the same concern — pairing drug access with lifestyle…
Your CFO Is Asking About GLP-1 Costs. Here’s How to Frame the Conversation.
Your CFO has seen the pharmacy numbers. The conversation is coming — if it hasn't already. GLP-1 spend is up. In some plans, it's among the fastest-growing pharmacy line items. And the questions you're getting aren't about the clinical evidence anymore. They're about the budget. Why are we paying this much? Is it going to…